Canthevac's Interferon-integrated Vaccine Platform (IVP) is a cutting-edge technology that enables the development of highly effective vaccines. By integrating interferon, a protective human cytokine, into the vaccine, it helps stimulate a strong immune response. This response involves both B-cell and T-cell immunity, which are crucial for fighting off infections. The IVP platform is designed to generate live-attenuated vaccines that can protect against different strains of sarbecovirus, including those that cause epidemics. 

To ensure safety, the vaccine undergoes genetic modifications that prevent it from undergoing further replication or infecting other cells in the body. This helps minimize the risk of vaccine-induced diseases while still inducing an effective immune response. The vaccine is manufactured using specialized vaccine-producing cells that stably express specific viral proteins. 

The vaccine is administered through intranasal injection, delivering it directly to the respiratory tract's mucosal surfaces. Once administered, the vaccine infects the respiratory epithelial cells and triggers the release of interferon. This, in turn, activates antiviral defenses in neighboring cells and boosts mucosal T-cell immunity. The goal is to provide comprehensive protection against infections and reduce the likelihood of co-infections.